Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation

Inclusion Criteria: * Has a biopsy-confirmed diagnosis of NHL * Is in first or second complete remission or partial remission, defined for the purpose of this study as complete or partial response following first- or second-line therapy * Treatment with an autologous peripheral HSC transplant is planned and the patient is eligible for autologous transplantation * Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Has recovered from all acute toxic effects of prior chemotherapy or other cancer treatment. * Has an actual body weight \<175% of their ideal body weight (IBW) * The patient agrees to use a highly effective method of contraception from Day 1 through ≥3 months following plerixafor treatment. Exclusion Criteria: * Concurrent serious illness and pathological conditions * Has undergone previous HSC collections or collection attempt * Has had any autologous or allogeneic HSC transplant * Has active central nervous system (CNS) involvement * Bone marrow lymphoma cells involvement \>20%, as assessed by bone marrow biopsy within 4 months before signing the ICF * Has received radiation therapy to the pelvis * Has a diagnosis of all leukemias including any type of CLL * Active infection * Pregnant or nursing * Anticipated post-transplant chemotherapy and/or radiation therapy below the diaphragm * Received any prior radio-immunotherapy * Prior 1,3-bis(2-chloroethyl)-1-nitroso-urea (BCNU) within 6 weeks prior to first dose of G-CSF * Prior cancer therapy, other investigational therapy within 4 weeks prior to first dose of G-CSF * Prior granulocyte/macrophage-colony stimulating factor (GM-CSF) or pegfilgrastim within 3 weeks prior to the first dose of G-CSF * Prior G-CSF within 2 weeks prior to the first dose of G-CSF * Inadequate organ funtion evidenced by unacceptable laboratory result